Immediate Impact
1 by Nobel laureates 48 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
H2AX: A key player in DNA damage response and a promising target for cancer therapy
2024 Standout
Works of Lorena Fariñas-Madrid being referenced
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
2020
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Lorena Fariñas-Madrid | 193 | 92 | 50 | 88 | 20 | 257 | |
| Robert C. Squatrito | 125 | 63 | 34 | 71 | 14 | 255 | |
| M K Heatley | 81 | 70 | 79 | 59 | 17 | 249 | |
| Kristen Bunch | 97 | 91 | 36 | 135 | 17 | 295 | |
| Elena Giudice | 119 | 66 | 37 | 82 | 27 | 203 | |
| Valerie Heong | 129 | 68 | 25 | 100 | 25 | 229 | |
| Maria M. Rubinstein | 95 | 99 | 111 | 77 | 23 | 271 | |
| Sang Young Ryu | 202 | 191 | 65 | 81 | 16 | 333 | |
| Koji Nishino | 83 | 87 | 47 | 112 | 20 | 246 | |
| Yuichi Imai | 104 | 51 | 34 | 135 | 20 | 285 | |
| Antonia Wenners | 100 | 52 | 24 | 101 | 21 | 299 |
All Works
Loading papers...